首页 | 本学科首页   官方微博 | 高级检索  
检索        

血清抗存活素抗体水平在肺部良恶性肿瘤中的对照研究
引用本文:张卫红,侯静朴,王国臣,李作生.血清抗存活素抗体水平在肺部良恶性肿瘤中的对照研究[J].中国综合临床,2011,27(5).
作者姓名:张卫红  侯静朴  王国臣  李作生
作者单位:河北联合大学附属医院胸心外科,唐山,063000
摘    要:目的 比较血清抗存活素抗体水平在肺部良、恶性肿瘤之间表达的差异,为将抗存活素抗体作为非小细胞肺癌筛查指标提供依据.方法 采用ELISA法检测健康体检者60名(对照组)、肺良性病变60例(肺良性病变组)、非小细胞肺癌60例(非小细胞肺癌组)血清中抗存活素抗体的含量.结果 抗存活素抗体在对照组11.7%(7/60)]中几乎不表达,在肺良性病变组中表达率为20.0%(12/60)],两者之间表达差异无统计学意义.在非小细胞肺癌组的外周血中阳性表达率68.3%(41/60),与肺良性病变组之间表达差异有统计学意义(x2=38.352,P<0.01),与对照组比较差异亦有统计学意义(x2=41.798,P<0.01).结论 抗存活素抗体在健康人群及肺良性病变患者中不表达,而在非小细胞肺癌中高表达,可为非小细胞肺癌诊断提供重要依据,并可作为非小细胞肺癌的筛查指标.
Abstract:
Objective To compare the serum anti-survivin antibody levels between benign and malignant lung tumor,thus to provide evidence for using anti-survivin antibody as an indicator in non-small cell lung cancer.Methods ELISA was used to measure the level of anti-survivin antibody in healthy population(control group,n=60),benign lung tumor patients(benign lung tumor group,n=60) and non-small cell lung cancer patients(non-small cell lung cancer group,n=60). Results The anti-surviving antibody did not express 11.7%(7/60) in the control group and almost no expression 20.0%(12/60) in the benign lung tumor group,with no significant difference between the two groups(P>0.05).In the non-small cell lung cancer group,the anti-survivin antibody expressed in 41 patients,which was significantly higher than those in the benign lung tumor group(x2=38.352,P<0.01).Conclusion Anti-survivin antibody does not express in the healthy population and the benign lung tumor patients,whereas shows high expression in non-small cell lung cancer.This finding indicates that anti-survivin antibody can provide important evidence for non-small cell lung cancer diagnosis,and can be used as an indicator for non-small lung cancer screening.

关 键 词:抗存活素抗体  非小细胞肺癌  存活素  鳞癌  腺癌  肺良性病变

Comparison of serum anti-survivin antibody levels between benign and malignant lung tumor
ZHANG Wei-hong,HOU Jing-pu,WANG Guo-chen,LI Zuo-sheng.Comparison of serum anti-survivin antibody levels between benign and malignant lung tumor[J].Clinical Medicine of China,2011,27(5).
Authors:ZHANG Wei-hong  HOU Jing-pu  WANG Guo-chen  LI Zuo-sheng
Abstract:Objective To compare the serum anti-survivin antibody levels between benign and malignant lung tumor,thus to provide evidence for using anti-survivin antibody as an indicator in non-small cell lung cancer.Methods ELISA was used to measure the level of anti-survivin antibody in healthy population(control group,n=60),benign lung tumor patients(benign lung tumor group,n=60) and non-small cell lung cancer patients(non-small cell lung cancer group,n=60). Results The anti-surviving antibody did not express 11.7%(7/60) in the control group and almost no expression 20.0%(12/60) in the benign lung tumor group,with no significant difference between the two groups(P>0.05).In the non-small cell lung cancer group,the anti-survivin antibody expressed in 41 patients,which was significantly higher than those in the benign lung tumor group(x2=38.352,P<0.01).Conclusion Anti-survivin antibody does not express in the healthy population and the benign lung tumor patients,whereas shows high expression in non-small cell lung cancer.This finding indicates that anti-survivin antibody can provide important evidence for non-small cell lung cancer diagnosis,and can be used as an indicator for non-small lung cancer screening.
Keywords:Anti-survivin antibody  non-small lung cancer  Survivin  Squamous carcinoma  Adenocarcinoma  Lung benign pathological change
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号